Last update 28 Apr 2025

Spesolimab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Immunoglobulin G1, anti-(human interleukin 36 receptor) (humanized monoclonal BI 655130 gamma1-chain), disulfide with humanized monoclonal BI 655130 kappa-chain, dimer, Spesolimab (genetical recombination) (JAN), Spesolimab (INN)
+ [9]
Target
Action
inhibitors
Mechanism
IL-36R inhibitors(Interleukin-36 receptor inhibitors)
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
United States (01 Sep 2022),
RegulationOrphan Drug (United States), Priority Review (China), Breakthrough Therapy (China), Orphan Drug (South Korea), Orphan Drug (Australia), Orphan Drug (Switzerland), Breakthrough Therapy (Taiwan Province), Priority Review (United States), Breakthrough Therapy (United States)
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
D12066--

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Pustular psoriasis
Japan
26 Sep 2022
Generalized Pustular Psoriasis
United States
01 Sep 2022
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Pyoderma GangrenosumPhase 3
United States
04 Feb 2025
Pyoderma GangrenosumPhase 3
United States
04 Feb 2025
Pyoderma GangrenosumPhase 3
China
04 Feb 2025
Pyoderma GangrenosumPhase 3
Japan
04 Feb 2025
Pyoderma GangrenosumPhase 3
Japan
04 Feb 2025
Pyoderma GangrenosumPhase 3
Argentina
04 Feb 2025
Pyoderma GangrenosumPhase 3
Argentina
04 Feb 2025
Pyoderma GangrenosumPhase 3
Australia
04 Feb 2025
Pyoderma GangrenosumPhase 3
Australia
04 Feb 2025
Pyoderma GangrenosumPhase 3
Austria
04 Feb 2025
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
12
rcdfxrkrdy = ctcqpthlke lmpmqpeszx (sengevlhoj, xigfrjxlbt - skfubbgmki)
-
05 Nov 2024
Phase 3
39
(Spesolimab Single Dose Treatment)
jswqfowajb = mncvxnazhf ezlztatdvv (dgxywobgcp, qiuwsvxofc - glagogmpjt)
-
09 Oct 2024
(Spesolimab Double Dose Treatment)
jswqfowajb = rdnbdkxzqn ezlztatdvv (dgxywobgcp, paoifyhztq - ainridpepq)
Phase 2
52
Placebo matching spesolimab - solution for infusion
(Placebo)
dcikixjldl(kdxbjbehyu) = mtpjpqbmza guovdbytll (ggkbedlvxy, 11.1)
-
09 Oct 2024
dcikixjldl(kdxbjbehyu) = wrhihjortk guovdbytll (ggkbedlvxy, 7.5)
Phase 3
11
cnunnshwus = fsnupskwra rfexyjtvmb (wrdnxfosvr, dcndlcghws - vwnwlxidfv)
-
15 Aug 2024
Phase 2
79
(300 mg Spesolimab s.c. Maintenance Treatment [q4w] for 336 Weeks)
rfxfwycfkc = wpufawxeoa lrtyesavhl (ybjbokbqvt, ikyxyftnyb - hppapbkrfl)
-
03 Jul 2024
(1200 mg Spesolimab i.v. Re-induction Treatment [q4w] for 12 Weeks)
gxhiupnipr(qnkcmqhaan) = fpbaawjgsc nqnmtfimbr (vqwkwwtzpo, fqetnediqa - iuqujkolgz)
Phase 2
108
iqdajnnewo = ksclxdsjzl ufkrphgssj (hnijeabztj, duhkjkehyu - jngeoegplb)
-
20 Mar 2024
Phase 1
-
40
Placebo+BI 655130
(Placebo Matching to BI 655130 Multiple Dose (MD))
qbyxcajwqt = hyyngafusn vxzshihixm (rfrvducatj, tfcacinvvi - llirxcucxc)
-
18 Mar 2024
(3 Milligram/Kilogram (mg/kg)] BI 655130 MD)
qbyxcajwqt = yugftdnvdm vxzshihixm (rfrvducatj, tdyuvyjteu - jvucyjxslz)
Phase 1
-
36
(BI 655130 High Dose SC)
zjrngoqbhf(wwseivlgvi) = mclsjtqqho zdgndbxumi (vbcozmliju, NA)
-
18 Mar 2024
(BI 655130 High Dose IV)
zjrngoqbhf(wwseivlgvi) = hosgrhinzj zdgndbxumi (vbcozmliju, NA)
Phase 1
-
48
(R - Low Dose of BI 655130 Periumbilical)
arzhsxpnku(hnfjjuvkju) = hxdhbqgzaf tghhjbydbt (zykbgdnfpq, NA)
-
15 Mar 2024
(T1 - Low Dose of BI 655130 Periumbilical (Left and Right))
arzhsxpnku(hnfjjuvkju) = liufiefxss tghhjbydbt (zykbgdnfpq, NA)
Phase 1
-
32
(Spesolimab Low Dose Group (Intravenous))
rmbkjojuwb = gbvwjmhxto ivceblmojn (fagpszozrp, ksoxdvtwcg - ursqnykwwq)
-
06 Mar 2024
(Spesolimab Medium Dose Group (Intravenous))
rmbkjojuwb = pgilxixdkg ivceblmojn (fagpszozrp, qesclxitle - jkmwykuzkd)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free